Available compounds per May 2022
–
| Drug | Target genes |
| Abemaciclib | CCND1, CCND3, CDK4, CDK6, CCND2, CCND1 3’UTR |
| Alectinib | ALK |
| Alpelisib | PIK3CA, PIK3R1/2, PTEN |
| Atezolizumab + bevacizumab | TMB-H ≥ 16 mut/Mb (all panels) |
| Axitinib | KDR, FLT4 |
| Crizotinib | ALK, MET, MST1R, ROS1 |
| Dabrafenib | BRAF V600 |
| Dabrafenib + trametinib | BRAF |
| Dacomitinib | EGFR, HER2, HER4 |
| Durvalumab | MSI |
| Erdafitinib | FGFR1, FGFR2, FGFR3, FGFR4 |
| Erlotinib | EGFR |
| Entrectinib | ROS1 |
| Lenvatinib | FGFR1, FGFR2, FGFR3, FGFR4 |
| Lorlatinib | ALK, ROS1 |
| Nilotinib | KIT, ABL1, PDGFRa, PDGFRb |
| Nivolumab + ipilimumab | HML: >199 and < 000, TMB-H:15–39 (TSO500) or 11–24 (Oncomine pane) |
| Olaparib | ATM, BARD1, BRCA1/2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD50, RAD51B, RAD51C, RAD51D, RAD54L |
| Panitumumab | RAF/RAS wildtype |
| Selpercatinib | RET |
| Sunitinib | CSF1R, FGFR1, FGFR2, FGFR3, FLT3, KDR, FLT4, KIT, PDGFRa, PDGFRb, RET |
| Talazoparib | ATM, ATR, FANCA, FANCC, FANCD2, FANCF, FANCM, RAD51, RAD51B, RAD54L, NBN, MRE11, BARD1, BRIP1, CHEK1, CHEK2, PALB2, PRA1, HRD signature |
| Trametinib | MAP2K1 (MEK1), MAP2K2 (MEK2), MAP2K4, MAP3K1, NRAS, GNA11, GNAQ, GNAS, BRAF, NF1 |
| Trastuzumab + pertuzumab | HER2 |
| Vemurafenib + cobimetinib | BRAF |
| Vismodegib | PTCH1 |
Onderstaand een overzicht van de geopende cohorten. Indien een geschikte patiënt zich voordoet die niet in een van deze cohorten past, kan er in overleg met het studieteam een nieuw cohort geopend worden.
| Drug | Tumor type | Target | Status |
| Abemaciclib | Esophageal | CCND3 amp | Open |
| Abemaciclib | Glioblastoma | CDK4 amp | Open |
| Abemaciclib | HNSCC | CCND1 amp | Open |
| Abemaciclib | Melanoma | CCND1 amp | Open |
| Abemaciclib | NSCLC | CCND1 amp | Open |
| Abemaciclib | Ovarian | CCND1 amp | Open |
| Abemaciclib | Prostate | CCND1 amp | Open |
| Abemaciclib | Sarcoma | CDK4 amp | Open |
| Abemaciclib | SCC bladder | CCND1 amp | Open |
| Abemaciclib | Urachal cancer | CCND1 amp | Open |
| Abemaciclib | Carcinoma of the small intestine | CCND3amp | Open |
| Abemaciclib | Carcinoma of the small intestine | CDK4 amp | Open |
| Abemaciclib | Urinary tract | CCND1 amp | Open |
| Abemaciclib | Melanoma | CDK4 amp | Open |
| Abemaciclib | Astrocytoma | CCND1 amp | Open |
| Afatinib | NSCLC | NRG1 fusion | Closed |
| Alectinib | Tumor-agnostic | ALK fusion | Open |
| Alectinib | Tumor-agnostic | ALK mut/amp | Open |
| Alpelisib | Tumor-agnostic | Double hit | Open |
| Alpelisib | Anal cancer | PIK3R2 mut | Open |
| Alpelisib | Gynaecological tumors | AKT1 mut | Closed |
| Alpelisib | Gynaecological tumors | PTEN loss | Open |
| Alpelisib | Gynaecological tumors | PIK3R1 mut | Open |
| Alpelisib | Gynaecological SCC | PIK3CA mut | Open |
| Alpelisib | Gynaecological PCC | PIK3CA mut | Open |
| Alpelisib | HNSCC | PIK3Ca mut | Open |
| Alpelisib | Miscellaneous tumors | PIK3CA mut | Open |
| Alpelisib | NEC cervical | PTEN loss | Open |
| Alpelisib | Prostate | PIK3CA mut | Open |
| Alpelisib | Prostate | PTEN loss | Open |
| Alpelisib | Renal cell | PTEN loss | Open |
| Alpelisib | Salivary gland | PTEN loss | Open |
| Alpelisib | Upper-GI | PIK3CA mut | Open |
| Alpelisib | Radiation associated sarcoma/sarcomatoid carcinoom | PTENloss | Open |
| Alpelisib | Folliculair schildkliercarcinoom | PTEN loss | Open |
| Atezolizumab + bevacizumab | Tumor-agnostic | TMB ≥16 mut/Mb | Open |
| Axitinib | CRC | FLT1 amp | Closed |
| Cabozantinib | Esophageal | MET mut | Closed |
| Cabozantinib | GIST | NTRK2 mut | Closed |
| Cabozantinib | Melanoma | MET amp | Closed |
| Cabozantinib | NSCLC | Ret fusion | Closed |
| Cabozantinib | Esophageal | RET mut | Closed |
| Cabozantinib | NSCLC | MET mut | Closed |
| Cabozantinib | Teratoma | MET amp | Closed |
| Crizotinib | ACUP | ALK fusion | Open |
| Crizotinib | Biliary tract | ALK mut | Open |
| Crizotinib | Colorectal | ALK mut | Open |
| Crizotinib | Colorectal | MET amp | Open |
| Crizotinib | Esophageal | MET amp | Open |
| Crizotinib | Gastric | MET amp | Open |
| Crizotinib | Inflammatory myofibrlastic tumor | ALK fusion | Open |
| Crizotinib | Hepatocellular | MET amp | Open |
| Crizotinib | NSCLC | MET amp | Open |
| Crizotinib | NSCLC | MET mut | On hold |
| Crizotinib | T cell lymphoma | ALK mut | Open |
| Crizotinib | Thyroid | ALK mut | Open |
| Crizotinib | Thyroid | MET fusion | Open |
| Crizotinib | Gynaecological tumors | MET amp | Open |
| Crizotinib | Sarcoma | ALK | Open |
| Crizotinib | Renal cell | MET mut | Open |
| Dabrafenib | Glioblastoma | BRAF V600 mut | Open |
| Dabrafenib | Urinary tract | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Biliary tract | BRAF V600 mut | Open |
| Dabrafenib + trametinib | GIST | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Glioblastoma | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Glioma (grade 3) | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Low grade glioma | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Mamma | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Neuroendocrine carcinoma colon | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Pancreas | BRAF V600 mut | Open |
| Dabrafenib + trametinib | NSCLC | BRAF V600 mut | Closed |
| Dacomitinib | Biliary tract | EGFR ampl | Open |
| Dacomitinib | Breast | HER2 mut | Open |
| Dacomitinib | Cervix | HER2 mut | Open |
| Dacomitinib | Colorectal | EGFR amp | Open |
| Dacomitinib | Colorectal | HER2 amp | Open |
| Dacomitinib | Endometrial | HER2 amp | Open |
| Dacomitinib | Endometrial | HER2 mut | Open |
| Dacomitinib | Esophageal | HER2 amp | Open |
| Dacomitinib | Gastro-esophageal junction | HER2 amp | Open |
| Dacomitinib | Penile | HER2 fusion | Open |
| Dacomitinib | Penile | EGFR amp | Open |
| Dacomitinib | Sarcoma | EGFR fusion | Open |
| Dacomitinib | Slokdarm | EGFR ampl | Open |
| Dacomitinib | Urinary tract | EGFR amp | Open |
| Dacomitinib | Vagina | HER2 mut | Open |
| Dacomitinib | Vulvar | EGFR ampl | Open |
| Durvalumab | Tumor-agnostic | MSI | Closed |
| Erdafitinib | NSCLC | FGFR1ampl | Open |
| Erdafitinib | Ovarian | FGFR1ampl | Open |
| Erdafitinib | Pancreas | FGFR3ampl | Open |
| Erdafitinib | Plexus choroidea carcinoma | FGFR2ampl | Open |
| Erdafitinib | Breast | FGFR1amp | Open |
| Erlotinib | CRC | EGFR mut | Open |
| Erlotinib | GBM | EGFR fusion | Open |
| Erlotinib | GBM | EGFR mut | On hold |
| Lenvatinib | Adenoid cystic carcinoma | FGFR2 mut | Open |
| Lenvatinib | ACUP | FGFR2 fusion | Open |
| Lenvatinib | Ameloblastoma | FGFR2 mut | Open |
| Lenvatinib | Anal cancer | FGFR3 mut | Open |
| Lenvatinib | Anaplastic thyroid | FGFR3 mut | Open |
| Lenvatinib | Biliary tract | FGFR2 fusion | Open |
| Lenvatinib | Biliary tract | FGFR3 fusion | Open |
| Lenvatinib | Biliary tract | FGFR2 mut | Open |
| Lenvatinib | Biliary tract | FGFR3 mut | Open |
| Lenvatinib | Cervix | FGFR3 mut | Open |
| Lenvatinib | Colorectal | FGFR1 amp | Open |
| Lenvatinib | Colorectal | FGFR2 amp | Open |
| Lenvatinib | Endometrium | FGFR2 mut | Open |
| Lenvatinib | Endometrium | FGFR3 amp | Open |
| Lenvatinib | Esophageal | FGFR2 amp | Open |
| Lenvatinib | Glioblastoma | FGFR3 fusion | Open |
| Lenvatinib | Glioneural tumor | FGFR1 mut | Open |
| Lenvatinib | Glioma | FGFR1 mut | Open |
| Lenvatinib | GBM | FGFR3 mut | Open |
| Lenvatinib | HNSCC | FGFR3 mut | Open |
| Lenvatinib | Mamma | FGFR1 amp | Open |
| Lenvatinib | Mamma | FGFR2 amp/mut | Open |
| Lenvatinib | Neuroendocrine nasal cavity | FGFR3 amp | Open |
| Lenvatinib | NSCLC | FGFR1 amp | Open |
| Lenvatinib | NSCLC | FGFR2 amp | Open |
| Lenvatinib | NSCLC | FGFR3 fusion | Open |
| Lenvatinib | Osteosarcoma | FGFR1 amp | Open |
| Lenvatinib | Pancreas | FGFR1 amp | Open |
| Lenvatinib | Pancreas | FGFR2 fusion | Open |
| Lenvatinib | Papillary cancer | FGFR2 mut | Open |
| Lenvatinib | Salivary gland | FGFR3 amp | Open |
| Lenvatinib | Salivary duct | FGFR2 mut | Open |
| Lenvatinib | Sarcoma | FGFR3 fusion | Open |
| Lenvatinib | Urachal cancer | FGFR2 amp | Open |
| Lenvatinib | Urinary tract | FGFR3 mut | Open |
| Lenvatinib | Vagina | FGFR3 mut | Open |
| Lorlatinib | Inflammatory myofibrolastic tumor | ALK fusion | Open |
| Lorlatinib | NSCLC | ROS1 fusion | Open |
| Nilotinib | Colorectal | PDGFRB amp | Open |
| Nilotinib | Germ cell | KIT mut | Open |
| Nilotinib | GIST | KIT mut | Open |
| Nilotinib | GIST | PDGFRA mut | Open |
| Nilotinib | Melanoma | KIT mut | Open |
| Nilotinib | Mesothelioma | PDGFRA mut | Open |
| Nivolumab | Tumor-agnostic | MSI (2nd stage) | Closed |
| Nivolumab | Tumor-agnostic | MSI (3rd stage) | On hold |
| Nivolumab | Tumor-agnostic | HML >450 | Closed |
| Nivolumab + ipilimumab | Tumor-agnostic | HML 200-1000 | Open |
| Olaparib | Tumor-agnostic | BRCA mut/loss | Closed |
| Olaparib | Tumor-agnostic | ATM mut/loss | Open |
| Olaparib | Tumor-agnostic | HRR alterations (breast, ovarian, prostate, pancreas, SCLC or stomach carcinoma) | Open |
| Olaparib | Tumor-agnostic | HRR alterations (all other tumor types) | Open |
| Panitumumab | ACUP | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Anal cancer | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Cervix | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Endometrium | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Glioblastoma | BRAF-KRAS-NRAS wildtype | On hold |
| Panitumumab | Gynaecological SCC | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | HNSCC | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Meningioma | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | (uvual) melanoma | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | NSCLC | BRAF-KRAS-NRAS wildtype + EGFR mut/amp | Open |
| Panitumumab | Salivary duct | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Sarcoma | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Thyroid | BRAF-KRAS-NRAS wildtype | Open |
| Palbociclib | Astrocytoma | CDK4 amp | Closed |
| Palbociclib | Biliary tract | CDKN2A loss/mut | Closed |
| Palbociclib | Colorectal | CCND2 amp | Closed |
| Palbociclib | Colorectal | CDKN2A loss/mut | Closed |
| Palbociclib | Colorectal | SMARCA4 mut | Closed |
| Palbociclib | Duodenal | CDKN2A loss/mut | Closed |
| Palbociclib | Endometrial carcinoma | CDKN2A loss/mut | Closed |
| Palbociclib | Esophageal | CDK4 amp | Closed |
| Palbociclib | Esophageal | CDKN2A loss/mut | Closed |
| Palbociclib | Glioblastoma | CDKN2A loss/mut | Closed |
| Palbociclib | HNSCC | CDKN2A loss/mut | Closed |
| Palbociclib | Melanoma | CCND1 amp | Closed |
| Palbociclib | Melanoma | CDKN2A loss/mut | Closed |
| Palbociclib | Neuroendocrine tumor | CDKN2A loss/mut | Closed |
| Palbociclib | Neuroendocrine tumor | CCND1 amp | Closed |
| Palbociclib | NSCLC | CCND1 amp | Closed |
| Palbociclib | NSCLC | CDKN2A loss/mut | Closed |
| Palbociclib | (uvual) melanoma | CDKN2A loss/mut | Closed |
| Palbociclib | Ovarian | CDKN2A loss/mut | Closed |
| Palbociclib | Ovarian | SMARCA4 mut | Closed |
| Palbociclib | Pancreas | CDKN2A loss/mut | Closed |
| Palbociclib | PECoom | CDK4 amp | Closed |
| Palbociclib | Primitive Neuro-ectodermal tumor | CDKN2A loss/mut | Closed |
| Palbociclib | Prostate | CDK4 amp | Closed |
| Palbociclib | Prostate | CDK6 amp | Closed |
| Palbociclib | Renal cell | CDKN2A loss/mut | Closed |
| Palbociclib | Sarcoma | CDK4 amp | Closed |
| Palbociclib | Vulva carcinoma | CDKN2A loss/mut | Closed |
| Palbociclib | Vulva carcinoma | CCND1 amp | Closed |
| Pembrolizumab | Colorectal | HML 140-290 | Closed |
| Pembrolizumab | HNSCC | HML 140-290 | Closed |
| Pembrolizumab | Mamma | HML 140-290 | Closed |
| Pembrolizumab | Miscellaneous tumors | HML 140-290 | Closed |
| Pembrolizumab | Prostate | HML 140-290 | Closed |
| Pembrolizumab | Upper-GI | HML 140-290 | Closed |
| Pembrolizumab | Tumor-agnostic | HML > 290 | Closed |
| Regorafenib | Adenoid cystic carcinoma | BRAF mut | Closed |
| Regorafenib | Duodenal | FLT1 amp | Closed |
| Regorafenib | Melanoma | KIT mut | Closed |
| Regorafenib | Esthesioneuroblastoma | RET | Closed |
| Regorafenib | NSCLC | RAF1 mut | Closed |
| Regorafenib | NSCLC | RET | Closed |
| Regorafenib | Thymus | KIT mut | Closed |
| Ribociclib | Anaplastic meningeoma | CDKN2A loss/mut | Closed |
| Ribociclib | ACUP | CDKN2A loss/mut | Closed |
| Ribociclib | Ceruminous adenocarcinoma | CDKN2A loss/mut | Closed |
| Ribociclib | Ependymoma | CDKN2A loss/mut | Closed |
| Ribociclib | Gastric cancer | CDKN2A loss/mut | Closed |
| Ribociclib | Melanoma | CDK4 amp | Closed |
| Ribociclib | Mesothelioma | CDKN2A loss/mut | Closed |
| Ribociclib | Mucoepidermoid | CDK6 amp | Closed |
| Ribociclib | Prostate | CDKN2A loss/mut | Closed |
| Ribociclib | Salivary gland | CDKN2A loss/mut | Closed |
| Ribociclib | Sarcoma | CDKN2A loss/mut | Closed |
| Ribociclib | Thymus | CDKN2A loss/mut | Closed |
| Ribociclib | Urinary tract | CDKN2A loss/mut | Closed |
| Rucaparib | Mamma | HRR alterations | Closed |
| Rucaparib | Miscellaneous tumors | HRR alterations | Closed |
| Rucaparib | Ovarian | HRR alterations | Closed |
| Rucaparib | Pancreas | HRR alterations | Closed |
| Rucaparib | Prostate | HRR alterations | Closed |
| Sunitinib | Adenoid cystic carcinoma | PDGFRA amp | Open |
| Sunitinib | Colorectal | CSF1R mut | Open |
| Sunitinib | Colorectal | FLT3 mut | Open |
| Sunitinib | Colorectal | FLT3 amp | Open |
| Sunitinib | Mamma | PDGFRB amp | Open |
| Sunitinib | NSCLC | KIT amp | Open |
| Sunitinib | Osteosarcoma | PDFGRB mut | Open |
| Sunitinib | Ovarian | FGFR1 amp | Open |
| Sunitinib | Ovarian | FGFR2 amp | Open |
| Sunitinib | Pancreas | RET fusion | Open |
| Sunitinib | Pseudomyxoma peritonei | FLT3 mut | Open |
| Sunitinib | Prostate | PDFGRA mut | Open |
| Sunitinib | Thymus | KIT mut | Open |
| Sunitinib | Thyroid cancer | PDGFRA mut | Open |
| Sunitinib | Thyroid cancer | PDGFRB mut | Open |
| Sunitinib | Urinary tract | FGFR1 amp | Open |
| Talazoparib | All tumor types | FANCA/FANCC/FANCD2/FANCF/FANC mut | Open |
| Talazoparib | All tumor types | other mutations in HRR genes (BARD1/BRIP1/CHECK1/2/PALB2/PRA1) | Open |
| Talazoparib | Tumor-agnostic | ATM/ATR alteraties | Open |
| Talazoparib | Tumor-agnostic | HRD signature | Open |
| Trametinib | ACUP | MAP2K1 mut | Open |
| Trametinib | ACUP | MAP3K1mut | Closed |
| Trametinib | Cervix | MAP3K1mut | Closed |
| Trametinib | Cholangiocarcinoma | MAP2K4 mut | Closed |
| Trametinib | Cholangiocarcinoma | NRASmut | Open |
| Trametinib | Colorectal | MAP2K4 mut | Closed |
| Trametinib | Colorectal | MAP2K1 mut | Open |
| Trametinib | Glioneural tumor | BRAF fusion | Open |
| Trametinib | Histiocytair sarcoma | MAP2K1mut | Open |
| Trametinib | Mamma | MAP3K1 mut | Closed |
| Trametinib | Mamma | MAP2K4 mut | Closed |
| Trametinib | Melanocytic tumor | GNA11 mut | Open |
| Trametinib | Neuroendocrine carcinoma | MAP3K1 mut | Closed |
| Trametinib | Neuroendocrine carcinoma | NRAS mut | Open |
| Trametinib | NSCLC | BRAF mut | Open |
| Trametinib | NSCLC | BRAF fusion | Open |
| Trametinib | NSCLC | MAP2K1 mut | Open |
| Trametinib | NSCLC | NRAS mut | Open |
| Trametinib | Ovarian | MAP2K4 mut | Closed |
| Trametinib | Ovarian | NRAS mut | Open |
| Trametinib | Pancreas | BRAF fusie | Open |
| Trametinib | Pancreas | MAP2K4 mut | Closed |
| Trametinib | (Pilocytic) astrocytoma | BRAF fusion | Open |
| Trametinib | Pleimorph tumor | NRAS mut | Open |
| Trametinib | Prostate | MAP3K1 mut | Closed |
| Trametinib | Prostate | NRAS mut | Open |
| Trametinib | Salivary duct | BRAF fusion | Open |
| Trametinib | Salivary duct | NRAS mut | Open |
| Trametinib | Thyroid | NRAs mut | Open |
| Trametinib | All tumor types | GNAS mut | Open |
| Trametinib | All tumor types | NF1 mut | On hold |
| Trametinib | All tumor types | MAP2K1 mut | Open |
| Trametinib | Urinary tract | BRAF fusion | Open |
| Trametinib | Yolk sac tumor | NRAS mut | Open |
| Trastuzumab + pertuzumab | Adenoid cystic carcinoma | HER2 mut | Open |
| Trastuzumab + pertuzumab | Biliary tract | HER2 amp | Open |
| Trastuzumab + pertuzumab | Cervix | HER2 amp | Open |
| Trastuzumab + pertuzumab | Cervix | HER2 mut | Open |
| Trastuzumab + pertuzumab | Colorectal | HER2 amp | Open |
| Trastuzumab + pertuzumab | Colorectal | HER2 mut | Open |
| Trastuzumab + pertuzumab | Duodenal | HER2 amp | Open |
| Trastuzumab + pertuzumab | Hidradenocarcinoma | HER2 amp | Open |
| Trastuzumab + pertuzumab | Melanoma | HER2 amp | Open |
| Trastuzumab + pertuzumab | Neuroendocrine carcinoma | HER2 amp | Open |
| Trastuzumab + pertuzumab | NSCLC | HER2 amp | Open |
| Trastuzumab + pertuzumab | NSCLC | HER2 mut | Closed |
| Trastuzumab + pertuzumab | Ovarian | HER2 amp | Open |
| Trastuzumab + pertuzumab | Ovarian | HER2 mut | Open |
| Trastuzumab + pertuzumab | Salivary duct | HER2 amp | Open |
| Trastuzumab + pertuzumab | Sinosal carcinoma | HER2 mut | Open |
| Trastuzumab + pertuzumab | Urinary tract | HER2 amp | Open |
| Trastuzumab + pertuzumab | Urinary tract | HER2 mut | Open |
| Trastuzumab + pertuzumab | Vulva | HER2 amp | Open |
| Vemurafenib + cobimetinib | ACUP | BRAF V600 mut | Open |
| Vemurafenib + cobimetinib | Erdheim Chester Disease | BRAF V600 mut | Open |
| Vemurafenib + cobimetinib | NSCLC | BRAF V600E mut NSCLC | Open |
| Vemurafenib + cobimetinib | NSCLC | BRAF non-V600 mut | Open |
| Vemurafenib + cobimetinib | Papillair craniopharyngeoma | BRAF V600 mut | Open |
| Vemurafenib + cobimetinib | Prostate | BRAF non-V600 mut | Open |
| Vemurafenib + cobimetinib | Thyroid | BRAF V600 mut | Open |
| Vemurafenib + cobimetinib | Ovarian | BRAF V600 mut | Open |
| Vemurafenib + cobimetinib | Salivary duct | BRAF V600 mut | Open |
| Vismodegib | Sarcoma | PTCH1 mut | Open |
| Vismodegib | CNS tumors | PTCH1 mut | Open |